Evaluation of Chromosomal Instability in Diabetic Rats Treated with Naringin

Table 1

DNA strand breaks in bone marrow of nondiabetic and diabetic rats 24 hours after the last treatment with the indicated doses of naringin (4 weeks exposures, spaced 24 hours apart) (mean ± SD).

Treatment groups (mg/kg)	Tail length (μm)	Tail DNA (%)	Tail moment (arbitrary unit)	Olive tail moment (arbitrary units)
Nondiabetic control	14.0 ± 4.8	5.98 ± 1.15	1.96 ± 0.61	4.78 ± 1.23
Nondiabetic + naringin (25)	12.6 ± 4.77	5.76 ± 1.52	2.12 ± 0.43	4.14 ± 0.56
Nondiabetic + naringin (50)	11.8 ± 4.71	4.82 ± 1.76	1.98 ± 0.23	3.20 ± 0.73
Diabetes	27.2 ± 4.91*	14.2 ± 3.39*	4.72 ± 0.54**	9.44 ± 2.03*
Diabetes + naringin (25)	18.6 ± 4.33^a	8.08 ± 1.54^b	2.98 ± 0.85^a	5.82 ± 1.27^b
Diabetes + naringin (50)	15.8 ± 3.96^b	6.97 ± 1.53^b	2.24 ± 0.7^b	4.32 ± 1.18^b

^∗𝑃<0.05 and ^∗∗𝑃<0.01 versus nondiabetic control (Kruskal-Wallis test followed by Dunn’s multiple comparisons test). ^a𝑃<0.05 and ^b𝑃<0.01 versus diabetes alone (Mann-Whitney U test).